Precigen reports results from Phase 1 PRGN-2012 study

Precigen announces positive Phase 1 dose escalation and expansion cohort data as of the January 12 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf, or OTS, AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis, or RRP. "RRP is a rare disease with no cure. The current standard-of-care is repeated surgery to treat symptoms, which exposes patients to surgical risks, emotional distress and poses a significant economic burden to families and the healthcare system overall. We are thrilled to present these Phase 1 results today as PRGN-2012 has the potential to improve the lives of patients with severe, aggressive RRP through reduced surgeries," said Helen Sabzevari, PhD, President and CEO of Precigen. "Any treatment that reduces the burden of surgeries in RRP is considered meaningful and in the PRGN-2012 Phase 1 study, 50% of patients had a Complete Response, requiring no surgeries as of the data cutoff with a minimum of 12 months following treatment."